AMPH Stock — Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc. (AMPH)

Updated October 16, 2026.

AMPH is a Stock. Total return is 195.7% over the past 12.3 years, 182.8 points behind SPY at 378.5%.

Amphastar Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and sells generic and proprietary injectable, inhalation, and intranasal medications in the United States, China, and France. Its product portfolio includes emergency treatments like BAQSIMI for severe hypoglycemia and naloxone for opioid overdose, as well as established drugs for asthma, anticoagulation, anesthesia, and other therapeutic areas. The company does not currently have an established dividend distribution program, making it oriented toward capital appreciation rather than income generation.

AMPH performance versus SPY

Price and return data through 2026-10-16.

Total return is 195.7% over the past 12.3 years, 182.8 points behind SPY at 378.5%. Over the past year its total return — price change plus distributions reinvested — is 11.4%. Its deepest 1-year drawdown was 42.6%.

AMPH key facts

Asset type

Stock

Asset class

Equity

Inception date

06/25/2014

Distribution frequency

None

Last close

$25.87 (as of 2026-10-16)

Market cap

$1,100,456,611

Average volume

352083.0

Beta

0.9

Payout ratio

0.0%

P/E ratio

15.31

Forward P/E

8.3041

EPS

$1.69

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AMPH risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 42.6%.

Who may consider AMPH — and who may not

It is a weaker fit for investors who need monthly cash flow (AMPH does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on AMPH

• All tickers starting with A

Tagged: Pharmaceutical.

Frequently asked questions